Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- With Right Infrastructure, “Bright Future”for Multinational Trials: Mr Morimoto of CMIC
July 4, 2011
- Sosei Group to Collaborate with Gifu Pharm. Univ.
July 4, 2011
- Korosho Instructs Revision of Package Inserts for Pioglitazone
July 4, 2011
- Korosho to Select 5 Hub Med. Institutions for Early-stage Clinical Studies
July 4, 2011
- Tsuruha HD: Dispensing Fees Up 10.2% in FY2010
July 4, 2011
- EMA to Issue Conclusion on Bladder Cancer Risk from Actos in July
July 4, 2011
- AnGes MG Obtains Patent on HVJ-E for Cancer
July 4, 2011
- R&I Upgrades Kaken's Rating from “Stable”to “Positive”
July 4, 2011
- Takeda Applies for SGN-35 in Europe
July 4, 2011
- Current Users to Be Permitted to Rely on Telemarketing to Buy Reclassified Class 2 OTC Drugs
July 4, 2011
- R&I Keeps AA- Rating for Eisai
July 4, 2011
- Merck Serono Stops Global Approval Process for Cladribine
July 4, 2011
- 3 Groups Reconfirm Opposition to Deregulating Online Sale of OTC Drugs
July 4, 2011
- Mebiopharm to Be Listed on TOKYO AIM on July 15
July 4, 2011
- Largest No. of New Drugs Listed in FY2010 in the Past 15 Years: FPMAJ
July 4, 2011
- JPA Presents Its Opinions on OTC Drug Risk Reclassification to Korosho
July 4, 2011
- Combined Sales of 23 Japanese Drug Companies Reach ¥100 billion in China
July 4, 2011
- Nihon Chouzai to Invest ¥10 Bil. to Increase GE Production Capacity
July 4, 2011
- Anticancer Drug Market in Japan to Exceed ¥1 Tril. in 2019: Fuji-Keizai
July 4, 2011
- Pfizer Japan to Promote Established Products with Force of 1,000
July 4, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…